Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reckitt Benckiser/Adams deal wraps

This article was originally published in The Tan Sheet

Executive Summary

U.K.-based Reckitt Benckiser completes the acquisition of Adams Respiratory Therapeutics, makers of Mucinex-brand cough/cold products, through a cash tender offer "followed by a short-form merger of its indirect wholly owned subsidiary, Twickenham, with and into Adams," the firm announces Jan. 30. Reckitt announced plans to pay remaining Adams shareholders $60 per share, the same price paid in the tender offer made in December 2007, the firm says (1"The Tan Sheet" Jan. 28, 2008, In Brief)...

You may also be interested in...

Mucinex supplemental NDA approved

More than a year after Reckitt Benckiser acquired Adams Respiratory Therapeutics, the firm receives FDA's approval to change the debossing of the modified release layer from "A" to "RB" on its MucinexExtended-Release Bi-Layer tablets, according to an April 3 approval letter for a supplemental new drug application (1"The Tan Sheet" Feb. 4, 2008, In Brief). The FDA also approved changing the tablet shape from round to modified oval and allows for blister packaging. Another April 3 FDA approval letter allows Reckitt to change the debossing of the MR layer of Mucinex DM Extended-Release Bi-Layer tablets from "Adams" to "RB.

Reckitt Raises Guidance On Adams Performance, Marketing Momentum

Reckitt Benckiser raises its 2008 sales targets based on the performance of brands added with its acquisition of Adams Respiratory Therapeutics early this year and heavy marketing investment in its latest quarter

Reckitt Benckiser closer to acquiring Adams

Reckitt Benckiser cleared another hurdle in its quest to purchase U.S.-based Adams Respiratory Therapeutics, completing its previously announced cash tender offer for all outstanding Adams' shares, UK-based firm reports. Reckitt received 95.9% of outstanding Adams' shares by the close of business Jan. 23. The firm plans to finalize the merger Jan. 29 and will pay $60 per share to remaining Adams' stockholders, the same price paid in the tender offer. The merger will expand the U.S. OTC presence of Reckitt, which also owns Boots Healthcare but is primarily a household cleaning business (1"The Tan Sheet" Dec. 17, 2007, p. 5)...





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts